Frequencies for first 10,000 rows of drug4cl1 variable in nhamcsopd2003 dataset : drug class #1 for medication #4 | Freq. Percent Cum. ----------------------------------------+----------------------------------- anesthetics, unspecified | 2 0.02 0.02 anesthetics, local (injectable) | 21 0.21 0.23 anesthetics, general | 23 0.23 0.46 adjuncts to anesthesia/analeptics | 7 0.07 0.53 anesthetics, topical | 1 0.01 0.54 anesthetics, rectal | 1 0.01 0.55 antidotes, specific | 6 0.06 0.61 penicillins | 10 0.10 0.71 cephalosporins | 9 0.09 0.80 erythromycins/lincosamides/macrolides | 9 0.09 0.89 sulfonamides and trimethoprim | 6 0.06 0.95 urinary tract antiseptics | 4 0.04 0.99 miscellaneous antibacterial agents | 5 0.05 1.04 quinolones/derivatives | 8 0.08 1.12 antifungals | 2 0.02 1.14 antiviral agents | 16 0.16 1.30 deficiency anemias | 25 0.25 1.55 anticoagulants/thrombolytics | 24 0.24 1.79 cardiac glycosides | 14 0.14 1.93 antiarrhythmic agents | 3 0.03 1.96 antianginal agents | 14 0.14 2.10 vascular disorders, cerebral/peripheral | 9 0.09 2.19 agents used to treat shock/hypotension | 6 0.06 2.25 antihypertensive agents | 39 0.39 2.64 diuretics | 56 0.56 3.20 coronary vasodilators | 1 0.01 3.21 relaxants/stimulants, urinary tract | 1 0.01 3.22 calcium channel blockers | 34 0.34 3.56 beta blockers | 51 0.51 4.07 alpha agonist/alpha blockers | 21 0.21 4.28 ace inhibitors | 43 0.43 4.71 sedatives and hypnotics | 34 0.34 5.05 antianxiety agents | 29 0.29 5.34 antipsychotic/antimanics | 24 0.24 5.58 antidepressants | 92 0.92 6.50 anorexiants/cns stimulants | 4 0.04 6.54 cns, miscellaneous | 2 0.02 6.56 alzheimer-type dementia | 3 0.03 6.59 antiemetics | 2 0.02 6.61 disorders, acid/peptic | 81 0.81 7.42 antidiarrheals | 5 0.05 7.47 laxatives | 23 0.23 7.70 miscellaneous gastrointestinals | 1 0.01 7.71 antispasmodics/anticholinergics | 2 0.02 7.73 antacids | 5 0.05 7.78 metabolic and nurtient agents, unspec.. | 1 0.01 7.79 hyperlipidemia | 81 0.81 8.60 vitamins/minerals | 49 0.49 9.09 nutrition, enteral/parenteral | 1 0.01 9.10 repl/regs of electrolytes/water balance | 31 0.31 9.41 calcium metabolism | 10 0.10 9.51 adrenal corticosteroids | 28 0.28 9.79 androgens/anabolic steroids | 4 0.04 9.83 estrogens/progestins | 17 0.17 10.00 blood glucose regulators | 74 0.74 10.74 thyroid/antithyroid | 23 0.23 10.97 contraceptives | 3 0.03 11.00 immunologic agents, unspecified | 1 0.01 11.01 vaccines/antisera | 83 0.83 11.84 immunomodulators | 8 0.08 11.92 allergenic extracts | 2 0.02 11.94 antiseptics/disinfectants | 4 0.04 11.98 dermatologics, misc. | 10 0.10 12.08 topical steroids | 12 0.12 12.20 topical anti-infectives | 9 0.09 12.29 dermatitis/antipruritics | 3 0.03 12.32 topical analgesics | 1 0.01 12.33 extrapyramidal movement disorders | 4 0.04 12.37 myasthenia gravis | 1 0.01 12.38 skeletal muscle hyperactivity | 7 0.07 12.45 anticonvulsants | 52 0.52 12.97 antineoplastics, miscellaneous | 5 0.05 13.02 hormonal/biological response mod. | 1 0.01 13.03 antimetabolites | 4 0.04 13.07 antibiotics,alkaloids,enzymes | 2 0.02 13.09 dna damaging drugs | 8 0.08 13.17 ophthalmic drugs, unspecified | 1 0.01 13.18 glaucoma | 4 0.04 13.22 ocular anti-infective/anti-inflammatory | 5 0.05 13.27 otic, topical (misc) | 2 0.02 13.29 vertigo/motion sickness/vomiting | 15 0.15 13.44 analgesics/general | 3 0.03 13.47 analgesics, narcotic | 85 0.85 14.32 analgesics, non-narcotic | 78 0.78 15.10 antimigraine/other headaches | 6 0.06 15.16 antiarthritics | 16 0.16 15.32 antigout | 2 0.02 15.34 nsaid | 45 0.45 15.79 antiprotozoals | 4 0.04 15.83 antimalarials | 2 0.02 15.85 antiasthmatics/bronchodilators | 59 0.59 16.44 nasal decongestants | 8 0.08 16.52 antitussives/expectorants/mucolytics | 4 0.04 16.56 antihistamines | 46 0.46 17.02 cold remedies | 1 0.01 17.03 corticosteroid-inhalation/nasal | 35 0.35 17.38 miscellaneous/unclassified | 1 0.01 17.39 unclassified | 27 0.27 17.66 homeopathic products | 5 0.05 17.71 . | 8,229 82.29 100.00 ----------------------------------------+----------------------------------- Total | 10,000 100.00 by Jean Roth , jroth@nber.org , 28 Mar 2016